Tandem Diabetes Care prices upsized IPO at $15, at high end of the range


Shutterstock photo

Tandem Diabetes Care, which manufactures a next-generation insulin pump for diabetics, raised $120 million by offering 8.0 million shares at $15, the high end of the range of $13 to $15. The company had originally planned to offer 7.1 million shares. Tandem Diabetes Care plans to list on the NASDAQ under the symbol TNDM. Tandem Diabetes Care initially filed confidentially on 8/12/2013. BofA Merrill Lynch and Piper Jaffray acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: TNDM

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com